News >

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

Caroline Seymour
Published: Thursday, Mar 28, 2019

Rita S. Mehta, MD

Rita S. Mehta, MD

The frontline combination of fulvestrant (Faslodex) and anastrozole resulted in a sustained benefit in progression-free survival (PFS) and a significant improvement in overall survival (OS) compared with anastrozole alone in patients with postmenopausal, hormone receptor (HR)–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial (NCT00075764).1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication